Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other Non-Current Assets: 2015-2025

Historic Other Non-Current Assets for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $3.0 million.

  • Editas Medicine's Other Non-Current Assets fell 43.38% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 43.38%. This contributed to the annual value of $5.2 million for FY2024, which is 39.18% down from last year.
  • Per Editas Medicine's latest filing, its Other Non-Current Assets stood at $3.0 million for Q3 2025, which was down 28.78% from $4.2 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Other Non-Current Assets ranged from a high of $9.5 million in Q1 2024 and a low of $3.0 million during Q3 2025.
  • In the last 3 years, Editas Medicine's Other Non-Current Assets had a median value of $5.3 million in 2024 and averaged $6.0 million.
  • In the last 5 years, Editas Medicine's Other Non-Current Assets soared by 179.72% in 2021 and then slumped by 55.75% in 2025.
  • Editas Medicine's Other Non-Current Assets (Quarterly) stood at $6.8 million in 2021, then dropped by 22.87% to $5.3 million in 2022, then spiked by 63.49% to $8.6 million in 2023, then tumbled by 39.18% to $5.2 million in 2024, then tumbled by 43.38% to $3.0 million in 2025.
  • Its Other Non-Current Assets was $3.0 million in Q3 2025, compared to $4.2 million in Q2 2025 and $4.2 million in Q1 2025.